Published in Biochemistry on June 01, 2011
Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J Biol Chem (2011) 1.11
The endocannabinoids anandamide and virodhamine modulate the activity of the candidate cannabinoid receptor GPR55. J Neuroimmune Pharmacol (2012) 1.06
The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. J Biol Chem (2012) 1.05
Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily. J Biol Chem (2015) 1.00
Allosteric modulation of a cannabinoid G protein-coupled receptor: binding site elucidation and relationship to G protein signaling. J Biol Chem (2013) 0.91
A potential role for GPR55 in gastrointestinal functions. Curr Opin Pharmacol (2012) 0.90
Identifying ligands at orphan GPCRs: current status using structure-based approaches. Br J Pharmacol (2016) 0.90
Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry (2013) 0.88
A homology modeling study toward the understanding of three-dimensional structure and putative pharmacological profile of the G-protein coupled receptor GPR55. J Mol Graph Model (2012) 0.80
Pharmacological profiling of the hemodynamic effects of cannabinoid ligands: a combined in vitro and in vivo approach. Pharmacol Res Perspect (2015) 0.80
The therapeutic potential of orphan GPCRs, GPR35 and GPR55. Front Pharmacol (2015) 0.78
Peptide-guided targeting of GPR55 for anti-cancer therapy. Oncotarget (2016) 0.78
Role of GPR55 during Axon Growth and Target Innervation(1,2,3). eNeuro (2015) 0.77
Cannabinoid Receptor Interacting Protein (CRIP) 1a competition with β-arrestin for CB1 receptor binding sites. Mol Pharmacol (2016) 0.75
Lysophosphatidylinositol Signalling and Metabolic Diseases. Metabolites (2016) 0.75
Identification of Crucial Amino Acid Residues Involved in Agonist Signaling at the GPR55 Receptor. Biochemistry (2017) 0.75
A role for GPR55 in human placental venous endothelial cells. Histochem Cell Biol (2015) 0.75
Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol (1993) 64.61
Scalable molecular dynamics with NAMD. J Comput Chem (2005) 59.49
Crystal structure of rhodopsin: A G protein-coupled receptor. Science (2000) 28.60
High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science (2007) 20.32
Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature (2007) 14.06
Structure of a beta1-adrenergic G-protein-coupled receptor. Nature (2008) 11.97
GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science (2007) 11.74
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science (2008) 11.74
Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science (2010) 10.30
Modeling of loops in protein structures. Protein Sci (2000) 9.68
Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature (2011) 9.61
Structure of bovine rhodopsin in a trigonal crystal form. J Mol Biol (2004) 6.80
Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science (1996) 6.50
Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science (2010) 5.86
Crystal structure of metarhodopsin II. Nature (2011) 5.05
Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc Natl Acad Sci U S A (2002) 4.12
Structure of fully hydrated fluid phase lipid bilayers with monounsaturated chains. J Membr Biol (2006) 3.67
A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem (1997) 3.12
Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem (2002) 2.87
Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci U S A (2001) 2.58
Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun (2007) 2.18
Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem (2009) 1.91
A role for direct interactions in the modulation of rhodopsin by omega-3 polyunsaturated lipids. Proc Natl Acad Sci U S A (2006) 1.84
The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J (2008) 1.83
Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res (1999) 1.68
Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry (1996) 1.66
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A (2009) 1.63
Molecular-level organization of saturated and polyunsaturated fatty acids in a phosphatidylcholine bilayer containing cholesterol. Biochemistry (2004) 1.62
Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem (2009) 1.60
A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J Biol Chem (2010) 1.59
Internal hydration increases during activation of the G-protein-coupled receptor rhodopsin. J Mol Biol (2008) 1.58
The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain (2008) 1.54
Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling. J Biol Chem (2000) 1.49
An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem (2003) 1.43
Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J Biol Chem (1997) 1.42
The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene (2010) 1.36
2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J Biochem (2008) 1.33
The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene (2010) 1.32
N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol (2002) 1.28
Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J Biol Chem (2004) 1.26
Prokink: a protocol for numerical evaluation of helix distortions by proline. Protein Eng (2000) 1.24
FRET-based monitoring of conformational change of the beta2 adrenergic receptor in living cells. Biochem Biophys Res Commun (2006) 1.23
Simulaid: a simulation facilitator and analysis program. J Comput Chem (2010) 1.21
A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol (2010) 1.21
The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2). Mol Pharmacol (1999) 1.14
Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther (2011) 1.03
Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: evidence for possible CB2 deviation from a rhodopsin template. Mol Pharmacol (2005) 1.01
Construction of a 3D model of the cannabinoid CB1 receptor: determination of helix ends and helix orientation. Life Sci (1995) 0.99
Residues accessible in the binding-site crevice of transmembrane helix 6 of the CB2 cannabinoid receptor. Biochemistry (2008) 0.97
Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor. J Med Chem (2002) 0.97
Conformational memories with variable bond angles. J Comput Chem (2008) 0.87
An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell (2005) 5.60
Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron (2005) 4.78
Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci (2003) 4.50
Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci (2004) 4.44
Functional genomic screen for modulators of ciliogenesis and cilium length. Nature (2010) 3.63
Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A (2004) 3.60
Dishevelled 2 recruits beta-arrestin 2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4. Science (2003) 3.52
Food reward in the absence of taste receptor signaling. Neuron (2008) 3.37
Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron (2004) 2.76
Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol (2002) 2.76
A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell (2008) 2.76
Tryptophan hydroxylase-2 controls brain serotonin synthesis. Science (2004) 2.64
Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci U S A (2003) 2.62
Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol (2009) 2.60
Reactive oxygen species as a signal in glucose-stimulated insulin secretion. Diabetes (2007) 2.59
Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol (2002) 2.54
The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J Biol Chem (2002) 2.47
Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41
Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci U S A (2008) 2.23
The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci (2007) 2.22
Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction. Neuron (2006) 2.19
Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron (2003) 2.03
Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci (2002) 2.01
MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc Natl Acad Sci U S A (2009) 2.00
Mice deficient for the vesicular acetylcholine transporter are myasthenic and have deficits in object and social recognition. Neuron (2006) 1.98
Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A (2011) 1.98
Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg Med Chem (2005) 1.93
Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci (2007) 1.93
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease. Science (2009) 1.88
Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol (2010) 1.86
Pregnenolone can protect the brain from cannabis intoxication. Science (2014) 1.85
Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A (2008) 1.85
Elimination of the vesicular acetylcholine transporter in the striatum reveals regulation of behaviour by cholinergic-glutamatergic co-transmission. PLoS Biol (2011) 1.84
N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology (2007) 1.83
Effect of torsinA on membrane proteins reveals a loss of function and a dominant-negative phenotype of the dystonia-associated DeltaE-torsinA mutant. Proc Natl Acad Sci U S A (2004) 1.78
Dopaminergic control of sleep-wake states. J Neurosci (2006) 1.77
Persistent oxidative stress due to absence of uncoupling protein 2 associated with impaired pancreatic beta-cell function. Endocrinology (2009) 1.71
Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter. J Biol Chem (2002) 1.67
Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem (2009) 1.60
A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J Biol Chem (2010) 1.59
TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci U S A (2011) 1.55
Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter. Proc Natl Acad Sci U S A (2008) 1.52
Aberrant responses in social interaction of dopamine transporter knockout mice. Behav Brain Res (2004) 1.52
Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol (2002) 1.51
Enhanced rewarding properties of morphine, but not cocaine, in beta(arrestin)-2 knock-out mice. J Neurosci (2003) 1.49
Beta-arrestin 2 regulates zebrafish development through the hedgehog signaling pathway. Science (2004) 1.47
PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci (2009) 1.46
Vmat2 heterozygous mutant mice display a depressive-like phenotype. J Neurosci (2007) 1.45
Prolonged kappa opioid receptor phosphorylation mediated by G-protein receptor kinase underlies sustained analgesic tolerance. J Biol Chem (2003) 1.45
An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J Med Chem (2003) 1.43
Phosphoinositide 3-kinase regulates beta2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/beta-arrestin complex. J Cell Biol (2002) 1.40
Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biol Psychiatry (2012) 1.39
Novelty seeking and stereotypic activation of behavior in mice with disruption of the Dat1 gene. Neuropsychopharmacology (2005) 1.39
CB2 receptor activation attenuates microcirculatory dysfunction during cerebral ischemic/reperfusion injury. Microvasc Res (2009) 1.38
A beta-arrestin binding determinant common to the second intracellular loops of rhodopsin family G protein-coupled receptors. J Biol Chem (2005) 1.38
Smoothened signal transduction is promoted by G protein-coupled receptor kinase 2. Mol Cell Biol (2006) 1.38
RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms. J Biol Chem (2003) 1.32
Rab5 association with the angiotensin II type 1A receptor promotes Rab5 GTP binding and vesicular fusion. J Biol Chem (2001) 1.32
Molecular mechanism of human Nrf2 activation and degradation: role of sequential phosphorylation by protein kinase CK2. Free Radic Biol Med (2007) 1.31
Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol (2005) 1.31
beta-Arrestin/AP-2 interaction in G protein-coupled receptor internalization: identification of a beta-arrestin binging site in beta 2-adaptin. J Biol Chem (2002) 1.30
Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors. J Neurosci (2012) 1.29
N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol (2002) 1.28
Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci U S A (2003) 1.27
The vesicular acetylcholine transporter is required for neuromuscular development and function. Mol Cell Biol (2009) 1.27
CB(1) receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol (2012) 1.26
Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J Biol Chem (2004) 1.26
Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance. J Neurosci (2004) 1.26
G protein-coupled receptor kinase 2 in multiple sclerosis and experimental autoimmune encephalomyelitis. J Immunol (2005) 1.24
(-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol (2005) 1.24
Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther (2010) 1.24
Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol Pharmacol (2007) 1.24
G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal. Br J Pharmacol (2003) 1.23